---
figid: PMC3008616__6606008f1
figlink: /pmc/articles/PMC3008616/figure/fig1/
number: F1
caption: 'An overview of the EGFR pathway and its main downstream effectors (top).
  Expected outcomes of anti-EGFR (mAb) therapy (bottom): sensitivity (tumour response)
  when EGFR is activated (gain copy number, ligand overexpression, other unknown mechanisms)
  and downstream effectors are wild type (left); resistance (tumour development and
  metastasis) when downstream effectors such as KRAS, BRAF or PI3K are activated or
  PTEN is inactivated (right).'
pmcid: PMC3008616
papertitle: Molecular determinants of anti-EGFR sensitivity and resistance in metastatic
  colorectal cancer.
reftext: F Di Fiore, et al. Br J Cancer. 2010 Dec 7;103(12):1765-1772.
pmc_ranked_result_index: '30758'
pathway_score: 0.9244756
filename: 6606008f1.jpg
figtitle: EGFR pathway and its main downstream effectors (top)
year: '2010'
organisms:
- Homo sapiens
ndex: 399ba58a-df0a-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3008616__6606008f1.html
  '@type': Dataset
  description: 'An overview of the EGFR pathway and its main downstream effectors
    (top). Expected outcomes of anti-EGFR (mAb) therapy (bottom): sensitivity (tumour
    response) when EGFR is activated (gain copy number, ligand overexpression, other
    unknown mechanisms) and downstream effectors are wild type (left); resistance
    (tumour development and metastasis) when downstream effectors such as KRAS, BRAF
    or PI3K are activated or PTEN is inactivated (right).'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3CB
  - MAPK1
  - KRAS
  - PIK3R5
  - PIK3CA
  - PIK3CG
  - PIK3R6
  - PIK3R3
  - AKT1
  - PIK3CD
  - AKT2
  - PIK3R4
  - EGFR
  - AKT3
  - MAPK3
  - MAP2K2
  - PTEN
  - BRAF
  - MAP2K1
  - Cancer
  - Lung cancer
genes:
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: MEK/ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: KRAS
  symbol: KRAS
  source: hgnc_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: MEK/ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MEK/ERK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: MEK/ERK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
figid_alias: PMC3008616__F1
redirect_from: /figures/PMC3008616__F1
figtype: Figure
---
